Jarosław Fedorowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jarosław Fedorowski has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Artur Białkowski
School of Public Health, Centre of Postgraduate Medical Education of Warsaw, 01-826 Warsaw, Poland
1 shared publication - Daniel Śliż
3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland
1 shared publication - Dariusz Świetlik
Division of Biostatistics and Neural Networks, Medical University of Gdansk, 80-211 Gdańsk, Poland
1 shared publication - Eliza Blicharska
Department of Pathobiochemistry and Interdisciplinary Applications of Ion Chromatography, Medical University of Lublin, 1 Chodzki St., 20-093 Lublin, Poland
1 shared publication - Jameason D. Cameron
Children’s Hospital of Eastern Ontario (CHEO), 401 Smyth Rd., Ottawa, ON K1H 5B2, Canada
1 shared publication - Justyna Kaźmierczak
Polish Pharmacy Practice Research Network (PPPRN), 00-867 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2657
Concerns, Beliefs and Attitudes of Pharmacists About Medical Cannabis Use in Poland
Introduction: The global use of medical cannabis is steadily increasing. In Poland, medical cannabis was legalised in 2017; however, its use remains limited and not widely integrated into clinical practice. This study aimed to explore the attitudes, concerns, and beliefs of pharmacists and pharmacy students regarding the medical use of cannabis. Methods: A study was conducted in 2021 among 422 pharmacists and pharmacy students in Poland, primarily working in community pharmacies. Data were collected using a custom-designed questionnaire addressing beliefs, concerns, and professional experiences related to medical cannabis. Results: Nearly half of the respondents (48.9%) believe that cannabis should be used exclusively for medical purposes, while 47.6% support its use for both medical and recreational purposes following legalisation. A substantial majority (over 90%) consider cannabis effective for treating adults, with nearly 70% acknowledging its potential for treating children. Over 66% of respondents feel comfortable discussing medical cannabis with patients; however, fewer are confident in providing detailed advice about its use. The findings also highlight concerns about the long-term effects and potential legal implications of dispensing medical cannabis. Conclusions: Pharmacists and pharmacy students in Poland demonstrate openness to the medical use of cannabis and recognise its therapeutic potential. However, to enhance their ability to advise patients effectively, targeted educational initiatives are needed. These should focus on the clinical applications, safety, and long-term effects of cannabis, alongside strategies for addressing patient concerns and ensuring responsible usage.
- 22 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2657
Open AccessConcerns, Beliefs and Attitudes of Pharmacists About Medical Cannabis Use in Poland
Introduction: The global use of medical cannabis is steadily increasing. In Poland, medical cannabis was legalised in 2017; however, its use remains limited and not widely integrated into clinical practice. This study aimed to explore the attitudes, concerns, and beliefs of pharmacists and pharmacy students regarding the medical use of cannabis. Methods: A study was conducted in 2021 among 422 pharmacists and pharmacy students in Poland, primarily working in community pharmacies. Data were collected using a custom-designed questionnaire addressing beliefs, concerns, and professional experiences related to medical cannabis. Results: Nearly half of the respondents (48.9%) believe that cannabis should be used exclusively for medical purposes, while 47.6% support its use for both medical and recreational purposes following legalisation. A substantial majority (over 90%) consider cannabis effective for treating adults, with nearly 70% acknowledging its potential for treating children. Over 66% of respondents feel comfortable discussing medical cannabis with patients; however, fewer are confident in providing detailed advice about its use. The findings also highlight concerns about the long-term effects and potential legal implications of dispensing medical cannabis. Conclusions: Pharmacists and pharmacy students in Poland demonstrate openness to the medical use of cannabis and recognise its therapeutic potential. However, to enhance their ability to advise patients effectively, targeted educational initiatives are needed. These should focus on the clinical applications, safety, and long-term effects of cannabis, alongside strategies for addressing patient concerns and ensuring responsible usage.